{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-048740","form_type":"8-K","ticker":"ONCO","cik":"0001782107","company_name":"Onconetix, Inc.","filed_at":"2023-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.538679+00:00","generated_at":"2026-06-14T01:26:27.122183+00:00","sec_items":["1.01","2.01","3.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Blue Water Biotech acquires six FDA-approved drugs for $8.5M cash and 1M shares","bullets":["Total consideration $8.5M cash (payable in three tranches) plus 1.0M restricted shares of BWV common stock.","Assets include ZONTIVITY (PAD/MI), OTOVEL/CETRAXAL (otic), CONJUPRI (hypertension), TREZIX/NALFON (pain).","Closing subject to delivery of audited 2022 financials of seller’s parent and other customary conditions.","Company will manage assets during pre-closing period; Blue Water becomes commercial-stage biopharma."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-048740","json":"https://secwatch.observer/filing/0001213900-23-048740.json","markdown":"https://secwatch.observer/filing/0001213900-23-048740.md","text":"https://secwatch.observer/filing/0001213900-23-048740.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023048740/0001213900-23-048740-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023048740/ea180344-8k_bluewater.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T01:26:27.122183+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2eaf033176e9ab089b89a1b10064351fd1beb064","claim":"Onconetix, Inc. entered into Purchase Agreement with WraSer, LLC, Xspire Pharma, LLC, and Legacy-Xspire Holdings, LLC (effective 2023-06-13).","evidence_excerpt":"On June 13, 2023, Blue Water Biotech, Inc., a Delaware corporation (the “Company”), entered into an Asset Purchase Agreement (the “Purchase Agreement”) with WraSer, LLC, a Mississippi limited liability company, Xspire Pharma, LLC, a Mississippi limited liability company (collectively, the “Seller”), and Legacy-Xspire Holdings, LLC, a Delaware limited liability company and the parent company of the Seller (“Parent”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023048740/0001213900-23-048740-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"WraSer, LLC, Xspire Pharma, LLC, and Legacy-Xspire Holdings, LLC"},{"label":"Effective","value":"2023-06-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}